Abcam, ab267212, Human OAS3 knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
OAS3 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 5 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 5 bp deletion in exon 1,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-OAS3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The 2'-5'-oligoadenylate synthetase 3 (OAS3) protein also known as OAS03 OAS-treate or simply OAS003 plays an important role in the innate immune response to viral infections. OAS3 is a member of the 2'-5'-oligoadenylate synthetase family and possesses a mass of approximately 125 kDa. It is ubiquitously expressed in various tissues but shows higher expression levels in liver lung and spleen. This protein is involved in the synthesis of 2'-5'-linked oligoadenylates from ATP an activity which is important for antiviral defense mechanisms in the cell.
Biological function summary
OAS3 contributes to the host's defense by activating RNase L a ribonuclease that degrades viral and cellular RNA to limit viral replication. OAS3 functions as part of the larger oligoadenylate synthetase family complex which enhances its ability to mediate an efficient antiviral response. The protein requires double-stranded RNA often produced during viral infections to achieve activation. This activation links the detection of viral components directly to antiviral actions effectively curtailing the spread of the virus within the host.
Pathways
OAS3 participates in the interferon alpha/beta signaling pathway and the 2'-5'-oligoadenylate synthetase-RNase L pathway. These pathways are essential for mediating antiviral responses in innate immunity. In these pathways OAS3 interacts with related proteins such as RNase L and other members of the OAS family like OAS1 and OAS2 which collectively enhance the immune response against viral threats.
Alterations in OAS3 activity relate to diseases such as hepatitis and systemic lupus erythematosus (SLE). Abnormal OAS3 expression or function can affect host viral defense mechanisms contributing to chronic infection conditions like hepatitis. In SLE OAS3 alongside proteins like OAS1 and RNase L becomes relevant due to its role in inappropriately activating immune responses potentially leading to tissue damage. These insights into OAS3's role highlight its significance in both protective immunity and its potential involvement in autoimmunity.